跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT05682638
NCT05682638招募中3 期

A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 in Participants Aged 18 Years and Older

AIM Vaccine Co., Ltd.2 个研究点 分布在 1 个国家目标入组 34,000 人开始时间: 2023年1月30日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
34,000
试验地点
2
主要终点
The person-year incidence density of first episodes of virologically-confirmed symptomatic cases of COVID-19 of any severity occurring in SARS-CoV-2 naive participants in vaccine(100μg) group
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Older

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
是

入选标准

  • •Adults aged 18 years and older.
  • •Understand the content of the Informed Consent Form (ICF), and voluntarily sign the ICF (If the participant is unable to sign the ICF on his/her own due to illiteracy, an impartial witness is needed).
  • •Participants who are willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests, and other study procedures.
  • •Female participants of childbearing potential or partners of male participants:
  • •voluntarily agree to use effective contraception with their partners prior to the first vaccination and must agree to continue such precautions during the study until 3 months after full vaccination (including the initial set of vaccination and crossover set of vaccination). [Effective contraception includes oral contraceptives, injectable or implantable contraception, extended-release topical contraceptives, hormonal patches, intrauterine devices (IUDs), sterilization, abstinence, condoms (for male), diaphragms, cervical caps, etc.].
  • •For female participants: without childbearing potential (amenorrhea for at least 1 year or documented surgical sterilization) or have used effective contraception with a negative pregnancy test before each vaccination in this study.
  • •On the day of 1st dose of vaccination and 24 hours prior to vaccination, axillary temperatures <37.3°C/99.1°F.
  • •Healthy participants or participants with mild underlying disease [in a stable state without exacerbation (no admission to hospital or no major adjustment to treatment regimen, etc.) for at least 3 months prior to enrollment in this study].

排除标准

  • •History of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), or other coronavirus infections.
  • •Individuals using prescription medications for prophylaxis or treatment of SARS-CoV-2 (including vaccination of licensed COVID-19 vaccines).
  • •History of a previous laboratory-confirmed diagnosis of SARS-CoV-2 infection or COVID-
  • •History of allergy to any component of the study vaccine or history of severe allergic reaction to vaccine or drug (including but not limited to anaphylaxis, allergic laryngeal edema, anaphylactic purpura, thrombocytopenic purpura, or localized allergic necrosis (Arthus reaction)).
  • •Positive nucleic acid for SARS-CoV-2 in nasopharyngeal/oropharyngeal swab specimens.
  • •Positive HIV test results.
  • •A history or family history of convulsions, epilepsy, encephalopathy and psychosis.
  • •Malignant tumors in the active phase, malignant tumors not receiving adequate treatment, malignant tumors at potential risk of recurrence during the study period.
  • •Asplenia or functional asplenia, complete or partial splenectomy from any cause.
  • •Prolonged (defined as more than 14 days) use of immunosuppressive or other immunomodulatory drugs (e.g., corticosteroids, ≥20 mg/d prednisone or equivalent; however, inhaled and topical steroids are permitted) within 6 months prior to the 1st dose of investigational vaccine.
  • •Any other licensed vaccines given within 28 days prior to the study vaccination, or planned administration of vaccine(s) within 28 days after the 2nd dose in the blinded crossover vaccination.
  • •Have received immunoglobulin or other blood products within 3 months prior to enrollment or plan to receive them during the study period.
  • •Blood donation or blood loss ≥ 450 mL within 1 month prior to enrollment or planned to donate blood during the study period.
  • •Participants who have received any other investigational product within 1 month prior to enrollment or intent to participate in another clinical study at any time during the conduct of this study.
  • •Women who are pregnant or breastfeeding.
  • •Participants deemed unsuitable for participation in this study based on the investigator's assessment.

结局指标

主要结局

The person-year incidence density of first episodes of virologically-confirmed symptomatic cases of COVID-19 of any severity occurring in SARS-CoV-2 naive participants in vaccine(100μg) group

时间窗: From 14 days after the 2nd dose in the initial set of vaccination

次要结局

  • The seroconversion rate (SCR) of SARS-CoV-2 virus neutralizing antibody and S-protein IgG antibodies in seropositive participants at baseline of the initial set of vaccination or the day of crossover vaccination (whichever comes earlier)(14 days, 28 days, 3 months and 6 months after the 2nd dose)
  • The person-year incidence density of first episodes of virologically-confirmed cases of COVID-19 leading to death for SARS-CoV-2 naive participants(From 14 days after the 2nd dose in the initial set of vaccination)
  • The person-year incidence density of first episodes of virologically-confirmed moderate to severe cases of COVID-19 for SARS-CoV-2 naive participants(From 14 days after the 2nd dose in the initial set of vaccination)
  • The person-year incidence density of first episodes of virologically-confirmed severe cases of COVID-19 for SARS-CoV-2 naive participants(From 14 days after the 2nd dose in the crossover set of vaccination)
  • The person-year incidence density of first episodes of virologically-confirmed symptomatic cases of COVID-19 of any severity occurring for SARS-CoV-2 naive participants at different age strata (18-59 years, ≥60 years)(From 14 days after the 2nd dose in the initial set of vaccination)
  • The person-year incidence density of first episodes of virologically-confirmed symptomatic cases of COVID-19 of any severity occurring(From 7 days after the 2nd dose in the initial set of vaccination)
  • Incidence, severity and duration of each solicited (local and systemic) Adverse Event (AE)(Within 14 days post each dose in reactogenicity subgroup in the initial set of vaccination)
  • The person-year incidence density of first episodes of virologically-confirmed severe cases of COVID-19 for SARS-CoV-2 non-naive participants(From 14 days after the 2nd dose in the initial set of vaccination)
  • The person-year incidence density of first episodes of virologically-confirmed moderate to severe cases of COVID-19 for SARS-CoV-2 native participants(From 14 days after the 2nd dose in the crossover set of vaccination)
  • The person-year incidence density of first episodes of virologically-confirmed cases of COVID-19 leading to death regardless prior SARS-CoV-2 infection(From 14 days after the 2nd dose in the crossover set of vaccination)
  • Incidence, severity, and causality of Adverse Events of Special Interest (AESIs)(From the day of 1st dose in the initial set of vaccination to 12 months after the 2nd dose in crossover set of vaccination)
  • The person-year incidence density of first episodes of virologically-confirmed symptomatic cases of COVID-19 of any severity occurring for SARS-CoV-2 non-naive participants(From 14 days after the 2nd dose in the initial set of vaccination)
  • The person-year incidence density of first episodes of virologically-confirmed symptomatic cases of COVID-19 of any severity occurring regardless prior SARS-CoV-2 infection(From 14 days after the 2nd dose in the initial set of vaccination)
  • Incidence, severity, and causality of AEs occurring(0-28 days post each dose)
  • Incidence, severity, and causality of Serious Adverse Events (SAEs)(From the day of 1st dose in the initial set of vaccination to 12 months after the 2nd dose in crossover set of vaccination)
  • Incidence, severity, and causality of pregnancy events(From the day of 1st dose in the initial set of vaccination to 12 months after the 2nd dose in crossover set of vaccination)
  • Geometric mean Titer (GMT) of SARS-CoV-2 virus neutralizing antibody responses and S-protein IgG antibody responses in the crossover set of vaccination(28 days, 3 months, 6 months and 12 months after the 2nd dose)
  • Geometric mean Titer (GMT) of SARS-CoV-2 virus neutralizing antibody responses and S-protein IgG antibody responses of the initial set of vaccination or the day of crossover vaccination (whichever comes earlier)(14 days, 28 days, 3 months and 6 months after the 2nd dose)
  • Geometric mean Increase (GMI) of SARS-CoV-2 virus neutralizing antibody responses and S-protein IgG antibody responses of the initial set of vaccination or the day of crossover vaccination (whichever comes earlier)(14 days, 28 days, 3 months and 6 months after the 2nd dose)
  • Geometric mean Increase (GMI) of SARS-CoV-2 virus neutralizing antibody responses and S-protein IgG antibody responses in the crossover set of vaccination(28 days, 3 months, 6 months and 12 months after the 2nd dose)
  • The seroconversion rate (SCR) of SARS-CoV-2 virus neutralizing antibody and S-protein IgG antibodies in seropositive participants at baseline in the crossover set of vaccination(28 days, 3 months, 6 months and 12 months after the 2nd dose)
  • The seroconversion rate (SCR) of SARS-CoV-2 virus neutralizing antibody and S-protein IgG antibodies in seronegative participants at baseline of the initial set of vaccination or the day of crossover vaccination (whichever comes earlier)(14 days, 28 days, 3 months and 6 months after the 2nd dose)
  • The seroconversion rate (SCR) of SARS-CoV-2 virus neutralizing antibody and S-protein IgG antibodies in seronegative participants at baseline in the crossover set of vaccination(28 days, 3 months, 6 months and 12 months after the 2nd dose)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

已完成
3 期
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)COVID-19
NCT04904471WestVac Biopharma Co., Ltd.39,663
招募中
3 期
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects with higher risk myelodysplastic syndrome (Higher Risk-MDS).
2024-517247-31-00Ascentage Pharma Group Inc.490
已完成
3 期
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster StudyCOVID-19 Pandemic
NCT05096832Livzon Pharmaceutical Group Inc.10,381
进行中（未招募）
3 期
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase IIICOVID-19 Pandemic
NCT05096845Livzon Pharmaceutical Group Inc.22,500
已完成
3 期
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal CancerMetastatic Colorectal CancerMetastatic Colon Cancer
NCT04322539Hutchison Medipharma Limited691